SCHEMBL1667279

SCHEMBL1667279

CN(C)c1ccc(C(=O)Nc2ccc(C(=NOC(=O)c3ccccc3)c3ccc(NC(=O)c4ccc(N(C)C)cc4)cc3)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 2/20 0.59
MAPT P10636 4/20 0.58
KDM4E B2RXH2 4/20 0.58
ALDH1A1 P00352 6/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
RAB9A P51151 4/20 0.53
LMNA P02545 4/20 0.53
NPC1 O15118 3/20 0.53
PTPN1 P18031 1/20 0.53
HTT P42858 1/20 0.53
HSD17B10 Q99714 3/20 0.53
MCL1 Q07820 2/20 0.53
TP53 P04637 1/20 0.53
GAA P10253 1/20 0.52
NAMPT P43490 1/20 0.51
TSHR P16473 2/20 0.50
MAPK1 P28482 1/20 0.50
KMT2A Q03164 2/20 0.49
CACNA1B Q00975 1/20 0.49
APBA1 Q02410 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1662938 0.85 MAPT (0.58) KCNK3MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL1666586 0.84 KCNK3 (0.51) KCNK3MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL1663483 0.83 MAPT (0.49) MAPTKDM4EALDH1A1SMN1; SMN2RAB9A
SCHEMBL5982606 0.83 KCNK3 (0.77) KCNK3MAPTKDM4EALDH1A1SMN1; SMN2
Iodide SCHEMBL30758605 0.81 KCNK3 (0.74) KCNK3MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL1662867 0.81 NOX1 (0.54) KCNK3MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL3638309 0.80 KCNK3 (0.82) KCNK3MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL1665363 0.79 MAPT (0.60) KCNK3MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL1663045 0.79 KCNK3 (0.63) KCNK3MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL10892520 0.78 KCNK3 (0.65) KCNK3MAPTKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
EP-2488486-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES Ligand Pharmaceuticals Inc. (US) 2012-08-22 EP disclosed
WO-2012068406-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2012-05-24 WO disclosed
WO-2011046954-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS HGF, EPOR, MPL KCNK3 4685/4885MAPT 4622/4885KDM4E 3484/4885
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF KCNK3 4355/4885MAPT 4411/4885KDM4E 1944/4885
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF KCNK3 4355/4885MAPT 4411/4885KDM4E 1944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.